Description

Canary Wharf Group plc (“Canary Wharf Group”) has commenced construction of 25 Churchill Place at Canary Wharf, central London, which is to be the new office headquarters of the European Medicines Agency.

When completed, the building will stand at approximately 130m with 23 floors, including 19 floors of Grade A office space and incorporating four atria on the western elevation.

The building is set for completion in late 2014 and is symbolic, as it is the last office site on the original Canary Wharf masterplan to be developed. The building sits adjacent to Wood Wharf, a 4.6m sq. ft. mixed-use future development site, of which Canary Wharf Group purchased control from its former joint venture partners last month for a combined £90m.

25 Churchill Place will be one of the most environment-friendly buildings at Canary Wharf to date. Environmental features will deliver an expected ‘excellent' BREEAM environment performance rating and an Energy Performance Certificate (EPC) rating of 40 or better. Features include the latest ultra-efficient air-conditioning equipment that recycles the energy from exhaust air and photo voltaic cells to generate energy from the sun's rays.

Designed by one of the worlds pre-eminent architectural firms, Kohn Pederson Fox Associates, BP4 is the final building on the original Canary Wharf Master Plan to be built, and will provide over 550,000 sq ft of office space. The building is being designed to achieve an 'Excellent' BREEAM rating.

The building will incorporate a green roof, and low carbon technologies including solar hot water heating and photo voltaic cells on the roof. All major construction materials will be certified as coming from sustainable sources.
Superstructure construction is underway with completion of the project scheduled for July 2014.

Companies

Kohn Pedersen Fox Associates

Canary Wharf Group